Altre lingue X4 Pharmaceuticals, Inc.

Azioni

XFOR

US98420X1037

Tempo reale stimato Cboe BZX Altri mercati azionari 17:18:24 10/07/2024			Variaz. 5gg	Var. 1 gen.
0,63 ^USD	+6,06%		+11,21%	-25,13%

27/06	Le azioni di X4 Pharmaceuticals cadono dopo l'annuncio di dati di prova sul trattamento delle malattie croniche del sangue	MT
27/06	Transcript : X4 Pharmaceuticals, Inc. - Special Call

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000E Value Index	01/07
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 2000 Value Index	01/07
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Value Index	01/07
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index	01/07
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 2500 Value Index	01/07
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index	01/07
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia and Initiation of Pivotal Phase 3 CN Trial	28/06
X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment	27/06
Mavorixafor in Chronic Neutropenia: Interim Data from Phase 2 Trial Presentation 907.6 KB	27/06
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial	27/06
X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial	27/06
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/06
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia	29/05
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Sector Update: Health Care Stocks Higher Late Afternoon	09/05
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	09/05
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc	09/05
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility	09/05
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
X4 Pharmaceuticals: Q1 Earnings Snapshot	07/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue X4 Pharmaceuticals, Inc.

Azioni

XFOR

US98420X1037

Altre lingue

Filtri